이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Scholar Rock Holding 관리

관리 기준 확인 4/4

Scholar Rock Holding's CEO는 Jay Backstrom, Oct2022 에 임명되었습니다 의 임기는 1.67 년입니다. 총 연간 보상은 $ 4.11M, 15.2% 로 구성됩니다. 15.2% 급여 및 84.8% 보너스(회사 주식 및 옵션 포함). 는 $ 219.79K 가치에 해당하는 회사 주식의 0.032% 직접 소유합니다. 219.79K. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 7.7 년입니다.

주요 정보

Jay Backstrom

최고 경영자

US$4.1m

총 보상

CEO 급여 비율	15.2%
CEO 임기	1.7yrs
CEO 소유권	0.03%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	7.7yrs

최근 관리 업데이트

Recent updates

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Apr 15

Scholar Rock: Solid Data And Good Prospects

Jan 12

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07

If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today

Mar 01

We Think Scholar Rock Holding (NASDAQ:SRRK) Can Afford To Drive Business Growth

Jan 05

CEO 보상 분석

Jay Backstrom 의 보수는 Scholar Rock Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$183m
Dec 31 2023	US$4m	US$624k	-US$166m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$7m	US$159k	-US$135m

보상 대 시장: Jay 의 총 보상 ($USD 4.11M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.43M ).

보상과 수익: Jay 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jay Backstrom (69 yo)

1.7yrs

테뉴어

US$4,111,853

보상

Dr. Jay Thomas Backstrom, M.D., M.P.H., serves as Non-Executive Director of LAVA Therapeutics N.V. since June 2022. He serves as Director at Be Biopharma, Inc. since December 2021. He had served as a Direc...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jay Backstrom	President	1.7yrs	US$4.11m	0.032% $ 215.6k
Edward Myles	CFO, COO & Treasurer	3.9yrs	US$2.01m	0.051% $ 336.8k
Tracey Sacco	Chief Commercial Officer	1.3yrs	US$2.28m	0% $ 0
Mo Qatanani	Chief Scientific Officer	less than a year	데이터 없음	0.020% $ 130.0k
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	데이터 없음	데이터 없음
Junlin Ho	General Counsel & Corporate Secretary	4.3yrs	US$2.13m	0.093% $ 618.6k
Caryn Parlavecchio	Chief Human Resources Officer	2.8yrs	데이터 없음	0.046% $ 308.8k
Lisa Price	Senior Vice President of Human Resources	no data	데이터 없음	데이터 없음
Erin Moore	Senior Vice President of Finance	no data	데이터 없음	데이터 없음
Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	4.3yrs	데이터 없음	데이터 없음
Jing Marantz	Chief Medical Officer	1.6yrs	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: SRRK 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jay Backstrom	President	1.7yrs	US$4.11m	0.032% $ 215.6k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	10.6yrs	US$299.20k	0.047% $ 312.0k
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	데이터 없음
Amir Nashat	Independent Director	11.7yrs	US$295.70k	0.050% $ 334.1k
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	7.7yrs	US$305.70k	0.011% $ 75.1k
Leonard Zon	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kristina Burow	Independent Director	9.8yrs	US$300.34k	0.0067% $ 44.4k
Joan Massague	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
David Hallal	Independent Chairman of the Board	6.9yrs	US$416.70k	0.36% $ 2.4m
Scott L. Friedman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Barry Coller	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Joshua Reed	Independent Director	3.3yrs	US$305.70k	0% $ 0

7.7yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: SRRK 의 이사회는 경험(평균 재직 기간 7.7 년)으로 간주됩니다.

Scholar Rock Holding 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

Recent updates

Scholar Rock Holding Corporation Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CFO, COO & Treasurer recently sold US$85k worth of stock

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates

Price target decreased to US$44.67

Price target decreased to US$46.17

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Price target decreased to US$55.80

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Board Member notifies of intention to sell stock

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting